Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma

Abstract Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some patients with advanced hepatocellular carcinoma (HCC); however, other individuals do not respond favorably. Hence, identifying the biomarkers, t...

Full description

Bibliographic Details
Main Authors: Nan Zhang, Xu Yang, Mingjian Piao, Ziyu Xun, Yunchao Wang, Cong Ning, Xinmu Zhang, Longhao Zhang, Yanyu Wang, Shanshan Wang, Jiashuo Chao, Zhenhui Lu, Xiaobo Yang, Hanping Wang, Haitao Zhao
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Biomarker Research
Subjects:
Hepatocellular carcinoma
Programmed death-1
Programmed death ligand 1
Immune checkpoint inhibitors
Biomarker
Online Access:https://doi.org/10.1186/s40364-023-00535-z

Internet

https://doi.org/10.1186/s40364-023-00535-z

Similar Items